Paradigm Biopharmaceuticals Limited (PBIGF)

USD 0.14

(0.0%)

Market Cap (In USD)

54.71 Million

Revenue (In USD)

65.8 Thousand

Net Income (In USD)

-58.65 Million

Avg. Volume

883.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.1147-0.2738
PE
-
EPS
-
Beta Value
0.874
ISIN
AU000000PAR5
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC
Employee Count
-
Website
https://www.paradigmbiopharma.com
Ipo Date
2019-05-10
Details
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.